RKDA Arcadia Biosciences, Inc.
Price Chart
Executive Summary
Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% increase in Zola® coconut water sales, offset by the absence of prior-year GLA oil sales. The company improved its net loss significantly, reducing it by 67% due to lower SG&A expenses and non-operating gains, while securing $2.1 million from preferred investment option exercises after terminating a proposed business combination with Roosevelt Resources.
Key Financial Metrics
Actionable Insight
The termination of the Roosevelt deal removes near-term M&A upside, but the $2.1M cash injection and cost discipline may extend runway. Traders should monitor whether Zola's growth can offset legacy revenue losses and if new strategic alternatives emerge.
Key Facts
- Zola® revenues increased 17% year-over-year in 2025, driven by higher distribution and sales volume.
- Total 2025 revenue declined 4% to $4.858 million due to $756,000 in absent GLA oil sales from 2024.
- Net loss attributable to common stockholders improved 67% to $2.3 million in 2025 from $7.0 million in 2024.
- SG&A expenses decreased by $2.6 million year-over-year, contributing significantly to improved losses.
- Company secured $2.1 million in gross proceeds from exercise of preferred investment options.
- Proposed business combination with Roosevelt Resources was terminated.
Financial Impact
Revenue down 4% YoY ($187K decline), but net loss improved by $4.7M due to cost reductions and gains; $2.1M cash infusion strengthens near-term liquidity.
Risk Factors
- Continued reliance on non-operating gains masks weak core revenue performance.
- Termination of business combination reduces potential for near-term liquidity event or balance sheet relief.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263397 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 14, 2026
26d ago
|
8-K
| $0.9560 $0.9190 | ▲ +3.87% | ▲ +4.83% | $0.9250 (+3.24%) |
|
Apr 30, 2026
5w ago
|
10-K/A
| $1.12 $1.07 | ▼ −4.46% | ▼ −6.81% | $0.9250 (−17.41%) |
|
Apr 3, 2026
9w ago
|
8-K
| $1.30 $1.33 | ▼ −1.92% | ▲ +2.21% | $0.9250 (+28.85%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $1.47 $1.30 | ▼ −11.56% | ▼ −15.43% | $0.9250 (−37.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access